An Open Label Study of the Effect of Xeloda and Radiotherapy on Pathological Response Rate in Patients With Locally Advanced Rectal Cancer
Phase of Trial: Phase II
Latest Information Update: 01 Sep 2016
At a glance
- Drugs Capecitabine (Primary)
- Indications Rectal cancer
- Focus Therapeutic Use
- Sponsors Roche
- 02 Jun 2012 Planned number of patients changed from 44 to 66 as reported by EudraCT.
- 19 Sep 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 19 Sep 2011 Actual end date (Feb 2011) added as reported by ClinicalTrials.gov.